Multivariable logistic regression for risks of symptom domain prevalence and poor HRQOL between overall HSCT survivors and noncancer controls by accounting for chronic health conditions
| Risk factors . | Sensationabnormalities . | Motor/movementproblems . | Cardiacsymptoms . | Pulmonarysymptoms . | Pain . | Fatigue . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT survivors vs noncancer controls* | 3.2 (1.5-6.8) | 4.3 (1.2,15.4) | 2.0 (0.7-5.7) | 2.3 (0.6-8.0) | 0.7 (0.3-1.4) | 1.5 (0.5-4.7) |
| Age at survey | 1.1 (1.0-1.1) | 1.0 (1.0-1.1) | 1.0 (1.0-1.1) | 1.0 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.2 (0.7-2.1) | 0.6 (0.2-1.5) | 1.0 (0.4-2.2) | 0.6 (0.2-1.6) | 0.9 (0.6-1.5) | 1.5 (0.7-3.3) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.2 (0.6-2.4) | 0.7 (0.2-2.3) | 0.8 (0.3-2.2) | 0.6 (0.2-1.5) | 1.5 (0.8-2.8) | 0.7 (0.3-1.8) |
| Education | ||||||
| <College vs ≥college* | 1.1 (0.6-1.9) | 2.2 (0.8-6.4) | 0.7 (0.3-1.7) | 1.0 (0.4-2.5) | 1.0 (0.6-1.6) | 1.4 (0.6-3.1) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.3 (0.7-2.4) | 2.8 (0.9-8.7) | 2.3 (0.9-5.8) | 3.0 (1.0-8.7) | 0.8 (0.5-1.5) | 1.5 (0.6-3.6) |
| Cardiovascular† | 1.5 (0.6-3.6) | 1.8 (0.5-7.1) | 4.9 (1.6,15.1) | 0.9 (0.2-3.6) | 2.4 (0.7-8.0) | 3.4 (1.2-9.4) |
| Endocrine† | 1.5 (0.8-2.7) | 2.7 (1.0-7.3) | 0.5 (0.2-1.4) | 1.5 (0.6-4.1) | 1.2 (0.7-2.1) | 0.8 (0.3-2.0) |
| Gastrointestinal† | 2.0 (0.9-4.2) | 0.8 (0.2-3.1) | 3.4 (1.3-9.0) | 2.2 (0.7-6.5) | 0.9 (0.4-2.0) | 1.8 (0.7-4.9) |
| Neurology† | 1.6 (0.6-4.3) | NA | 0.3 (0.0-2.9) | 0.4 (0.1-3.7) | 3.9 (1.1-14.4) | 0.7 (0.2-3.5) |
| Ocular† | 2.2 (0.8-6.2) | 1.9 (0.5-8.0) | 1.2 (0.3-4.8) | 1.0 (0.2-4.5) | 4.5 (1.1-17.7) | 1.1 (0.3-4.5) |
| Pulmonary† | 1.4 (0.6-3.3) | 0.4 (0.1-2.3) | 3.6 (1.3-9.6) | 5.3 (1.8,15.6) | 1.5 (0.6-3.7) | 2.1 (0.8-5.9) |
| Reproductive† | 1.1 (0.6-2.3) | 0.8 (0.2-2.5) | 0.3 (0.1-1.0) | 1.7 (0.6-5.1) | 2.5 (1.1-5.6) | 1.5 (0.6-4.0) |
| Risk factors . | Sensationabnormalities . | Motor/movementproblems . | Cardiacsymptoms . | Pulmonarysymptoms . | Pain . | Fatigue . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT survivors vs noncancer controls* | 3.2 (1.5-6.8) | 4.3 (1.2,15.4) | 2.0 (0.7-5.7) | 2.3 (0.6-8.0) | 0.7 (0.3-1.4) | 1.5 (0.5-4.7) |
| Age at survey | 1.1 (1.0-1.1) | 1.0 (1.0-1.1) | 1.0 (1.0-1.1) | 1.0 (1.0-1.1) | 1.1 (1.0-1.1) | 1.1 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.2 (0.7-2.1) | 0.6 (0.2-1.5) | 1.0 (0.4-2.2) | 0.6 (0.2-1.6) | 0.9 (0.6-1.5) | 1.5 (0.7-3.3) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.2 (0.6-2.4) | 0.7 (0.2-2.3) | 0.8 (0.3-2.2) | 0.6 (0.2-1.5) | 1.5 (0.8-2.8) | 0.7 (0.3-1.8) |
| Education | ||||||
| <College vs ≥college* | 1.1 (0.6-1.9) | 2.2 (0.8-6.4) | 0.7 (0.3-1.7) | 1.0 (0.4-2.5) | 1.0 (0.6-1.6) | 1.4 (0.6-3.1) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.3 (0.7-2.4) | 2.8 (0.9-8.7) | 2.3 (0.9-5.8) | 3.0 (1.0-8.7) | 0.8 (0.5-1.5) | 1.5 (0.6-3.6) |
| Cardiovascular† | 1.5 (0.6-3.6) | 1.8 (0.5-7.1) | 4.9 (1.6,15.1) | 0.9 (0.2-3.6) | 2.4 (0.7-8.0) | 3.4 (1.2-9.4) |
| Endocrine† | 1.5 (0.8-2.7) | 2.7 (1.0-7.3) | 0.5 (0.2-1.4) | 1.5 (0.6-4.1) | 1.2 (0.7-2.1) | 0.8 (0.3-2.0) |
| Gastrointestinal† | 2.0 (0.9-4.2) | 0.8 (0.2-3.1) | 3.4 (1.3-9.0) | 2.2 (0.7-6.5) | 0.9 (0.4-2.0) | 1.8 (0.7-4.9) |
| Neurology† | 1.6 (0.6-4.3) | NA | 0.3 (0.0-2.9) | 0.4 (0.1-3.7) | 3.9 (1.1-14.4) | 0.7 (0.2-3.5) |
| Ocular† | 2.2 (0.8-6.2) | 1.9 (0.5-8.0) | 1.2 (0.3-4.8) | 1.0 (0.2-4.5) | 4.5 (1.1-17.7) | 1.1 (0.3-4.5) |
| Pulmonary† | 1.4 (0.6-3.3) | 0.4 (0.1-2.3) | 3.6 (1.3-9.6) | 5.3 (1.8,15.6) | 1.5 (0.6-3.7) | 2.1 (0.8-5.9) |
| Reproductive† | 1.1 (0.6-2.3) | 0.8 (0.2-2.5) | 0.3 (0.1-1.0) | 1.7 (0.6-5.1) | 2.5 (1.1-5.6) | 1.5 (0.6-4.0) |
| Risk factors . | Nausea . | Memory problems . | Anxiety . | Depression . | PCS (score ≤40) . | MCS (score ≤40) . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT survivors vs noncancer controls* | 1.0 (0.4-2.6) | 3.7 (1.5-8.9) | 1.9 (0.9-3.9) | 1.5 (0.7-3.3) | 5.4 (1.6-18.6) | 1.1 (0.5-2.6) |
| Age at survey | 1.0 (0.9-1.0) | 1.0 (1.0-1.1) | 1.0 (1.0-1.0) | 1.0 (1.0-1.1) | 1.1 (1.0-1.2) | 1.0 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.6 (0.8-3.3) | 0.9 (0.4-1.7) | 1.3 (0.8-2.3) | 0.9 (0.5-1.6) | 1.3 (0.5-3.1) | 1.4 (0.8-2.7) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.0 (0.4-2.4) | 0.9 (0.4-2.2) | 0.9 (0.5-1.7) | 0.7 (0.4-1.4) | 2.5 (0.6-9.6) | 1.5 (0.6-3.4) |
| Education | ||||||
| <College vs ≥college* | 1.4 (0.7-3.0) | 2.5 (1.1-5.3) | 1.5 (0.9-2.7) | 1.5 (0.8-2.7) | 2.2 (0.9-5.5) | 1.8 (1.0-3.5) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.2 (0.5-2.5) | 3.7 (1.6-8.4) | 1.2 (0.6-2.3) | 2.2 (1.1-4.2) | 2.5 (0.9-6.5) | 1.6 (0.8-3.2) |
| Cardiovascular† | 1.2 (0.4-3.9) | 1.0 (0.3-3.0) | 0.8 (0.3-2.1) | 0.8 (0.3-2.2) | 2.8 (0.9-8.1) | 0.9 (0.3-3.0) |
| Endocrine† | 1.2 (0.6-2.4) | 0.6 (0.2-1.3) | 1.1 (0.6-1.9) | 2.2 (1.2-4.0) | 3.2 (1.3-8.0) | 1.4 (0.7-2.7) |
| Gastrointestinal† | 3.2 (1.4-7.5) | 3.5 (1.5-8.3) | 2.8 (1.3-5.8) | 1.2 (0.5-2.8) | 2.5 (0.9-6.5) | 1.4 (0.6-3.4) |
| Neurology† | 0.6 (0.1-2.8) | 2.4 (0.8-7.6) | 1.4 (0.5-3.8) | 1.0 (0.3-2.8) | 3.3 (1.0-11.2) | 1.6 (0.6-4.5) |
| Ocular† | 1.0 (0.2-3.9) | 0.5 (0.2-1.8) | 0.7 (0.2-2.0) | 0.5 (0.1-1.8) | 1.6 (0.4-6.1) | 0.4 (0.1-1.9) |
| Pulmonary† | 1.1 (0.4-3.3) | 1.9 (0.7-4.8) | 2.0 (0.9-4.5) | 2.3 (1.0-5.5) | 1.3 (0.4-4.1) | 1.8 (0.7-4.7) |
| Reproductive† | 1.2 (0.5-3.2) | 1.5 (0.6-3.5) | 1.1 (0.5-2.2) | 1.2 (0.6-2.7) | 0.9 (0.3-2.3) | 1.8 (0.8-4.2) |
| Risk factors . | Nausea . | Memory problems . | Anxiety . | Depression . | PCS (score ≤40) . | MCS (score ≤40) . |
|---|---|---|---|---|---|---|
| OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | OR (95% CI) . | |
| Treatment group | ||||||
| Overall HSCT survivors vs noncancer controls* | 1.0 (0.4-2.6) | 3.7 (1.5-8.9) | 1.9 (0.9-3.9) | 1.5 (0.7-3.3) | 5.4 (1.6-18.6) | 1.1 (0.5-2.6) |
| Age at survey | 1.0 (0.9-1.0) | 1.0 (1.0-1.1) | 1.0 (1.0-1.0) | 1.0 (1.0-1.1) | 1.1 (1.0-1.2) | 1.0 (1.0-1.1) |
| Sex | ||||||
| Female vs male* | 1.6 (0.8-3.3) | 0.9 (0.4-1.7) | 1.3 (0.8-2.3) | 0.9 (0.5-1.6) | 1.3 (0.5-3.1) | 1.4 (0.8-2.7) |
| Race/ethnicity | ||||||
| White, non-Hispanic vs other* | 1.0 (0.4-2.4) | 0.9 (0.4-2.2) | 0.9 (0.5-1.7) | 0.7 (0.4-1.4) | 2.5 (0.6-9.6) | 1.5 (0.6-3.4) |
| Education | ||||||
| <College vs ≥college* | 1.4 (0.7-3.0) | 2.5 (1.1-5.3) | 1.5 (0.9-2.7) | 1.5 (0.8-2.7) | 2.2 (0.9-5.5) | 1.8 (1.0-3.5) |
| Marital status | ||||||
| Single/divorced/other vs married/living with partner* | 1.2 (0.5-2.5) | 3.7 (1.6-8.4) | 1.2 (0.6-2.3) | 2.2 (1.1-4.2) | 2.5 (0.9-6.5) | 1.6 (0.8-3.2) |
| Cardiovascular† | 1.2 (0.4-3.9) | 1.0 (0.3-3.0) | 0.8 (0.3-2.1) | 0.8 (0.3-2.2) | 2.8 (0.9-8.1) | 0.9 (0.3-3.0) |
| Endocrine† | 1.2 (0.6-2.4) | 0.6 (0.2-1.3) | 1.1 (0.6-1.9) | 2.2 (1.2-4.0) | 3.2 (1.3-8.0) | 1.4 (0.7-2.7) |
| Gastrointestinal† | 3.2 (1.4-7.5) | 3.5 (1.5-8.3) | 2.8 (1.3-5.8) | 1.2 (0.5-2.8) | 2.5 (0.9-6.5) | 1.4 (0.6-3.4) |
| Neurology† | 0.6 (0.1-2.8) | 2.4 (0.8-7.6) | 1.4 (0.5-3.8) | 1.0 (0.3-2.8) | 3.3 (1.0-11.2) | 1.6 (0.6-4.5) |
| Ocular† | 1.0 (0.2-3.9) | 0.5 (0.2-1.8) | 0.7 (0.2-2.0) | 0.5 (0.1-1.8) | 1.6 (0.4-6.1) | 0.4 (0.1-1.9) |
| Pulmonary† | 1.1 (0.4-3.3) | 1.9 (0.7-4.8) | 2.0 (0.9-4.5) | 2.3 (1.0-5.5) | 1.3 (0.4-4.1) | 1.8 (0.7-4.7) |
| Reproductive† | 1.2 (0.5-3.2) | 1.5 (0.6-3.5) | 1.1 (0.5-2.2) | 1.2 (0.6-2.7) | 0.9 (0.3-2.3) | 1.8 (0.8-4.2) |